Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says

Novo Nordisk's oral Wegovy reached approximately 137,000 total US prescriptions in its 18th week on the market, despite a 4% week-over-week decline. Citi's tracker says the pill continues to outpace its main competitor, suggesting still-strong early demand for the new formulation. The update is supportive for Novo Nordisk's weight-loss franchise, but the week-over-week decline keeps the read-through only modestly positive.

Analysis

The key takeaway is not the modest weekly dip, but the implied durability of demand for oral GLP-1s after the novelty phase. If prescriptions are still near peak levels in week 18, the market is likely underestimating how quickly this format can become a persistent share-capture engine versus injections, especially among patients who were previously hesitant due to administration friction. That is incrementally bullish for the platform economics of the franchise and suggests the competitive moat is shifting from pure efficacy to convenience plus distribution.

Second-order, the pressure is asymmetric for rivals with weaker brand pull or slower formulary adoption: once a lead oral product establishes habitual use, switching costs rise because patients and prescribers anchor on tolerability and refill cadence, not just trial data. The more important read-through is for the broader obesity basket: sustained oral growth may compress the window for newer entrants to differentiate, forcing them into price concessions, rebate escalation, or faster label-expansion strategies. In other words, the competitive battle may migrate from science to commercial execution sooner than consensus expects.

The main near-term risk is not demand collapse but sequencing risk: weekly volatility can mask a plateau if early adopters are exhausted and incremental patients prove less sticky. Over the next 1-3 months, watch whether prescription growth broadens across geographies, payers, and prescriber cohorts; if not, this could become a high-floor, low-upside trend rather than a breakout launch. Over 6-12 months, payer pushback or supply constraints could become the actual bottlenecks, which would matter more for estimate revisions than this week-to-week noise.

The market is likely still pricing oral GLP-1s as a nice-to-have extension rather than a format that could materially widen the total addressable market. That looks too conservative if convenience unlocks a meaningfully larger pool of treatment-naive or injection-averse patients. The contrarian issue is that the real upside may come not from cannibalizing the existing injectable base, but from adding incremental users who never would have started therapy at all.

Key Decisions for Investors

• Maintain/add NVO long exposure on 1-3 month horizon; use weakness to build, as the data supports continued launch durability and upside to obesity revenue estimates if weekly prescriptions stabilize above current levels.
• Buy NVO call spreads 3-6 months out to express upside while limiting premium burn; structure around a scenario where commercial momentum keeps compounding and estimate revisions follow.
• Short weaker obesity competitors selectively on relative strength into any rally if they lack comparable oral traction; the cleaner trade is long NVO vs. basket shorts, as the launch widens the moat through convenience and brand habit formation.
• Watch C as a read-through on data visibility and bank-sponsored tracker influence rather than a direct alpha trade; if the tracker continues to validate momentum, it can extend the rerating window for NVO.
• Set a tactical stop/review trigger if weekly prescriptions roll over for 2-3 consecutive weeks; that would argue the launch is entering maturity faster than expected and reduce conviction on the near-term growth slope.